Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
S&P Global
SPGI
|
$677M |
| 2 |
AGN
Allergan plc
AGN
|
$438M |
| 3 |
lululemon athletica
LULU
|
$407M |
| 4 |
Qualcomm
QCOM
|
$393M |
| 5 |
NVIDIA
NVDA
|
$376M |
Top Sells
| 1 |
Under Armour
UAA
|
$1.04B |
| 2 |
Abbott
ABT
|
$758M |
| 3 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
$627M |
| 4 |
Meta Platforms (Facebook)
META
|
$516M |
| 5 |
MON
Monsanto Co
MON
|
$453M |
Sector Composition
| 1 | Consumer Discretionary | 19.2% |
| 2 | Healthcare | 16.74% |
| 3 | Technology | 15.05% |
| 4 | Communication Services | 12.7% |
| 5 | Financials | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
476
Salarius Pharmaceuticals
SLRX
$2.39M
| $7.05M | 0.01% |
9
| – | – |
|
477
Provident Financial Services
PFS
$2.59B
| $6.89M | 0.01% |
350,968
-498,788
| -59% | -$9.8M |
|
|
AVXS
478
DELISTED
AveXis, Inc. Common Stock
AVXS
| $6.84M | 0.01% |
179,783
-218
| -0.1% | -$8.29K |
|
479
Spyre Therapeutics
SYRE
$1.01B
| $6.69M | 0.01% |
+55,523
| New | +$6.69M |
|
|
PSXP
480
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $6.42M | 0.01% |
114,904
-20,010
| -15% | -$1.12M |
|
481
MPLX
MPLX
$51B
| $5.92M | 0.01% |
+176,030
| New | +$5.92M |
|
|
AM
482
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $5.68M | 0.01% |
203,847
+9,265
| +5% | +$258K |
|
|
DSCI
483
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $5.57M | 0.01% |
1,413,534
-953
| -0.1% | -$3.76K |
|
484
MacroGenics
MGNX
$112M
| $5.29M | 0.01% |
196,162
-273
| -0.1% | -$7.37K |
|
485
USA Compression Partners
USAC
$2.84B
| $5.28M | 0.01% |
360,301
+16,729
| +5% | +$245K |
|
486
Syndax Pharmaceuticals
SNDX
$1.41B
| $5.25M | 0.01% |
537,545
+76,653
| +17% | +$748K |
|
487
Norfolk Southern
NSC
$61.9B
| $5.16M | 0.01% |
60,549
+12,785
| +27% | +$1.09M |
|
|
CMRX
488
DELISTED
Chimerix, Inc.
CMRX
| $5.04M | 0.01% |
1,282,604
-1,466
| -0.1% | -$5.76K |
|
489
Exxon Mobil
XOM
$466B
| $4.77M | 0.01% |
50,925
-1,117
| -2% | -$105K |
|
|
LNKD
490
DELISTED
LinkedIn Corporation
LNKD
| $4.65M | 0.01% |
24,592
-291,788
| -92% | -$55.2M |
|
|
ENBL
491
DELISTED
ENABLE MIDSTREAM PARTNERS, LP
ENBL
| $4.54M | 0.01% |
+335,976
| New | +$4.54M |
|
|
TRVN
492
DELISTED
Trevena, Inc.
TRVN
| $4.45M | ﹤0.01% |
1,130
-2
| -0.2% | -$7.88K |
|
493
Editas Medicine
EDIT
$251M
| $4.13M | ﹤0.01% |
170,940
| – | – |
|
|
LJPC
494
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $4.04M | ﹤0.01% |
252,437
+3,863
| +2% | +$61.8K |
|
|
VWR
495
DELISTED
VWR Corporation
VWR
| $3.97M | ﹤0.01% |
+137,373
| New | +$3.97M |
|
|
GBT
496
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.94M | ﹤0.01% |
237,172
-145
| -0.1% | -$2.41K |
|
497
BioCryst Pharmaceuticals
BCRX
$1.73B
| $3.85M | ﹤0.01% |
1,356,302
-1,302
| -0.1% | -$3.7K |
|
498
Plains GP Holdings
PAGP
$3.63B
| $3.56M | ﹤0.01% |
128,032
+5,668
| +5% | +$157K |
|
499
Johnson & Johnson
JNJ
$428B
| $3.49M | ﹤0.01% |
28,805
-678
| -2% | -$82.2K |
|
500
Gartner
IT
$18.5B
| $3.41M | ﹤0.01% |
34,999
| – | – |
|